PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35557600-8 2022 By preventing activated plasmin from de-stabilizing the fibrin matrix, TXA promotes clot formation. Tranexamic Acid 71-74 plasminogen Homo sapiens 24-31 16227196-11 2005 Epsilon aminocaproic acid and tranexamic acid are lysine analogs that reduce bleeding by inhibiting the conversion of plasminogen to plasmin, a serine protease responsible for breaking down fibrinogen to fibrin. Tranexamic Acid 30-45 plasminogen Homo sapiens 118-125 14572819-3 2003 The antifibrinolytic agents aprotinin, tranexamic acid, and epsilon-aminocaproic acid are useful for prophylaxis and treatment of angioedema, likely by inhibiting plasmin. Tranexamic Acid 39-54 plasminogen Homo sapiens 163-170 12846058-2 2003 OBJECTIVE: In the present study, the effects of plasmin antagonist tranexamic acid (TEA) on urinary pyridinoline excretion rates were investigated in rheumatoid arthritis (RA) patients. Tranexamic Acid 67-82 plasminogen Homo sapiens 48-55 12846058-2 2003 OBJECTIVE: In the present study, the effects of plasmin antagonist tranexamic acid (TEA) on urinary pyridinoline excretion rates were investigated in rheumatoid arthritis (RA) patients. Tranexamic Acid 84-87 plasminogen Homo sapiens 48-55 10930090-5 2000 In contrast, the effect of BCC-derived medium on collagen amount was attenuated by inhibitors of matrix metalloproteinases (MMPs) as well as by tranexamic acid, an inhibitor of the plasminogen conversion to plasmin, while it was abolished in presence of the two kinds of proteinase inhibitors. Tranexamic Acid 144-159 plasminogen Homo sapiens 181-188 10544908-3 1999 Our aim was to explore the effect of inhibiting both plasmin action with tranexamic acid (TA) and thrombin production with low molecular weight heparin (LMWH), on the bleeding time (BT) and platelet function in patients with CRF. Tranexamic Acid 73-88 plasminogen Homo sapiens 53-60 10544908-3 1999 Our aim was to explore the effect of inhibiting both plasmin action with tranexamic acid (TA) and thrombin production with low molecular weight heparin (LMWH), on the bleeding time (BT) and platelet function in patients with CRF. Tranexamic Acid 90-92 plasminogen Homo sapiens 53-60 9192782-6 1997 The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites. Tranexamic Acid 76-126 plasminogen Homo sapiens 4-11 9192782-6 1997 The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites. Tranexamic Acid 76-126 plasminogen Homo sapiens 163-170 9192782-6 1997 The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites. Tranexamic Acid 128-134 plasminogen Homo sapiens 4-11 9192782-6 1997 The plasmin-induced chemotactic response was inhibited by the lysine analog trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA), which prevents binding of plasmin/ogen to the appropriate membrane binding sites. Tranexamic Acid 128-134 plasminogen Homo sapiens 163-170 7925643-9 1994 Detachment was prevented by an anticatalytic anti-uPA antibody, by the plasmin-specific inhibitor aprotinin, and by the lysine analogue tranexamic acid, the latter of which prevents plasmin(ogen) binding to the cell surface. Tranexamic Acid 136-151 plasminogen Homo sapiens 182-189 8579642-1 1994 We reviewed the records of 66 patients who underwent cardiopulmonary bypass; half of these patients received the plasmin inhibitor, tranexamic acid. Tranexamic Acid 132-147 plasminogen Homo sapiens 113-120 7531000-0 1994 Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Tranexamic Acid 53-68 plasminogen Homo sapiens 72-79 7531000-7 1994 These results support the idea that aprotinin inhibition of plasmin is a primary mode of action in vivo, and suggest that combination therapy of aprotinin with tranexamic acid might be more effective than either inhibitor alone. Tranexamic Acid 160-175 plasminogen Homo sapiens 60-67 8383426-5 1993 Induction of the early phase of plasmin"s effect required both the lysine binding and catalytic sites in plasmin molecule because it was inhibited either by the binding antagonist tranexamic acid or by the serine protease inhibitor aprotinin. Tranexamic Acid 180-195 plasminogen Homo sapiens 32-39 8383426-5 1993 Induction of the early phase of plasmin"s effect required both the lysine binding and catalytic sites in plasmin molecule because it was inhibited either by the binding antagonist tranexamic acid or by the serine protease inhibitor aprotinin. Tranexamic Acid 180-195 plasminogen Homo sapiens 105-112 8383426-7 1993 The late phase of plasmin"s effect was due to the catalytic activity because it was inhibited by aprotinin but not by tranexamic acid. Tranexamic Acid 118-133 plasminogen Homo sapiens 18-25 1533399-7 1992 Pretreatment of PMN with either active-site-inhibited plasmin or tranexamic acid prevented PMN aggregation by plasmin, indicating that both binding of plasmin to the cell surface via the lysine binding sites and catalysis were required for the response. Tranexamic Acid 65-80 plasminogen Homo sapiens 110-117 1533399-7 1992 Pretreatment of PMN with either active-site-inhibited plasmin or tranexamic acid prevented PMN aggregation by plasmin, indicating that both binding of plasmin to the cell surface via the lysine binding sites and catalysis were required for the response. Tranexamic Acid 65-80 plasminogen Homo sapiens 110-117 1951300-4 1991 Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL). Tranexamic Acid 28-43 plasminogen Homo sapiens 58-65 1951300-4 1991 Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL). Tranexamic Acid 200-215 plasminogen Homo sapiens 58-65 1951300-4 1991 Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL). Tranexamic Acid 200-215 plasminogen Homo sapiens 150-157 1951300-4 1991 Follow-up in vitro study of tranexamic acid inhibition of plasmin-induced platelet activation utilizing normal human platelet rich plasma and porcine plasmin revealed a 13-fold lower concentration of tranexamic acid for 50% inhibition when plasmin was preincubated with the drug (1.2 micrograms/mL, 95% CI = 1.13-1.60 micrograms/mL) compared to when platelet rich plasma was preincubated with the drug (16 micrograms/mL, 95% CI = 7.3-99. micrograms/mL). Tranexamic Acid 200-215 plasminogen Homo sapiens 150-157 1951300-5 1991 Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets. Tranexamic Acid 25-40 plasminogen Homo sapiens 0-7 1951300-5 1991 Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets. Tranexamic Acid 25-40 plasminogen Homo sapiens 157-164 1951300-5 1991 Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets. Tranexamic Acid 132-147 plasminogen Homo sapiens 0-7 1951300-5 1991 Plasmin inactivated with tranexamic acid retained its ability to inhibit thrombin-induced platelet activation, thus suggesting that tranexamic acid inhibits plasmin"s catalytic activity and not its binding to platelets. Tranexamic Acid 132-147 plasminogen Homo sapiens 157-164 1951300-7 1991 Tranexamic acid blocks plasmin-induced partial platelet activation during ECC, thus preserving platelet function and promoting hemostasis after ECC. Tranexamic Acid 0-15 plasminogen Homo sapiens 23-30 1712633-4 1990 After incubation of the melanoma cells with 10% plasminogen-depleted fetal calf serum and human plasminogen, bound plasmin activity could be eluted from the cell surface with tranexamic acid, an analogue of lysine. Tranexamic Acid 175-190 plasminogen Homo sapiens 48-55 34065949-6 2021 Tranexamic acid is an antifibrinolytic agent which inhibits the conversion of plasminogen to plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 93-100 11927131-6 2002 Increasing concentrations of tranexamic acid resulted in a continuous increase of K(i initial) until a plateau was reached which was similar for all plasmin types. Tranexamic Acid 29-44 plasminogen Homo sapiens 149-156 11389038-4 2001 Plasmin-mediated mRNA expression was inhibited in a concentration-dependent manner by the lysine analogue trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA). Tranexamic Acid 106-156 plasminogen Homo sapiens 0-7 11389038-4 2001 Plasmin-mediated mRNA expression was inhibited in a concentration-dependent manner by the lysine analogue trans-4-(aminomethyl)cyclohexane-1-carboxylic acid (t-AMCA). Tranexamic Acid 158-164 plasminogen Homo sapiens 0-7 10959704-6 2000 Tranexamic acid (0.8 mM) is incorporated in the reaction mixture resulting in a 19-fold increase in the rate of plasminogen activation and presumably an about 50-fold decrease in the rate of inhibition of generated plasmin by plasmin inhibitor. Tranexamic Acid 0-15 plasminogen Homo sapiens 112-119 10959704-6 2000 Tranexamic acid (0.8 mM) is incorporated in the reaction mixture resulting in a 19-fold increase in the rate of plasminogen activation and presumably an about 50-fold decrease in the rate of inhibition of generated plasmin by plasmin inhibitor. Tranexamic Acid 0-15 plasminogen Homo sapiens 215-222 8654567-4 1996 Substantial reductions in k1 were seen in the presence of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid at concentrations corresponding to lysine-binding site interactions at kringle 4 of plasmin; at saturation the rate constant is reduced 20-fold, whereas the effect of saturation of kringle 1 is only a 2-fold reduction. Tranexamic Acid 58-108 plasminogen Homo sapiens 193-200 7679575-6 1993 Tranexamic acid inhibited the digestion of thrombospondin by plasmin and miniplasmin, suggesting an important role for the kringle-5 domain in this process. Tranexamic Acid 0-15 plasminogen Homo sapiens 61-68 8428801-4 1993 Plasmin generation was abolished and pro-u-PA accumulated in cell cultures that were grown for several days, either in the presence of serum thoroughly depleted of plasminogen, or in the presence of 1 mM tranexamic acid. Tranexamic Acid 204-219 plasminogen Homo sapiens 0-7 8428801-7 1993 Most of the bound plasmin could be washed off cells with 10 mM tranexamic acid, but complete removal of plasmin from the cell surface required washing of the cells with acid-glycine pH 3.0. Tranexamic Acid 63-78 plasminogen Homo sapiens 18-25 1703440-6 1991 In the presence of tranexamic acid or 6-aminohexanoic acid, lysine analogues that mimic the effects of fibrin, plasmin binding kinetics are changed such that equilibrium is reached slowly following a lag phase after mixing of enzyme and inhibitor. Tranexamic Acid 19-34 plasminogen Homo sapiens 111-118 34703327-1 2021 Tranexamic acid (TXA) is a lysine analog that exhibits an anti-fibrinolytic effect by directly preventing the activation of plasminogen as well as inhibiting activated plasmin from degrading fibrin clots, thereby promoting hemostasis and reducing the duration and quantity of blood loss. Tranexamic Acid 0-15 plasminogen Homo sapiens 168-175 34703327-1 2021 Tranexamic acid (TXA) is a lysine analog that exhibits an anti-fibrinolytic effect by directly preventing the activation of plasminogen as well as inhibiting activated plasmin from degrading fibrin clots, thereby promoting hemostasis and reducing the duration and quantity of blood loss. Tranexamic Acid 17-20 plasminogen Homo sapiens 168-175 35220154-2 2022 Tranexamic acid (TXA) reduces the proteolytic action of plasmin on fibrin clots, resulting in an inhibition of fibrinolysis and stabilisation of established blood clots. Tranexamic Acid 0-15 plasminogen Homo sapiens 56-63 35220154-2 2022 Tranexamic acid (TXA) reduces the proteolytic action of plasmin on fibrin clots, resulting in an inhibition of fibrinolysis and stabilisation of established blood clots. Tranexamic Acid 17-20 plasminogen Homo sapiens 56-63 35323992-1 2022 Tranexamic acid is a plasmin inhibitor that is used off-label for the treatment of melasma. Tranexamic Acid 0-15 plasminogen Homo sapiens 21-28 35388589-2 2022 Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss, and is also used to treat rosacea due to its anti-inflammatory effects. Tranexamic Acid 0-15 plasminogen Homo sapiens 32-39 35388589-2 2022 Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss, and is also used to treat rosacea due to its anti-inflammatory effects. Tranexamic Acid 17-20 plasminogen Homo sapiens 32-39 2551068-0 1989 Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin. Tranexamic Acid 14-29 plasminogen Homo sapiens 71-78 35095503-1 2021 Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 229-236 35095503-1 2021 Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Tranexamic Acid 17-19 plasminogen Homo sapiens 229-236 35095503-2 2021 Previous studies suggested that TA may exhibit anticancer activity by blockade of extracellular Plasmin formation. Tranexamic Acid 32-34 plasminogen Homo sapiens 96-103 35095503-4 2021 Results presented herein demonstrate that TA blocks Plasmin-mediated excision of the extracellular domain of the oncoprotein CDCP1. Tranexamic Acid 42-44 plasminogen Homo sapiens 52-59 35095503-6 2021 Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production. Tranexamic Acid 24-26 plasminogen Homo sapiens 242-249 35095503-6 2021 Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production. Tranexamic Acid 70-72 plasminogen Homo sapiens 242-249 35095503-6 2021 Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production. Tranexamic Acid 158-160 plasminogen Homo sapiens 242-249 2551068-0 1989 Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin. Tranexamic Acid 14-29 plasminogen Homo sapiens 118-125 2551068-1 1989 The addition of tranexamic acid inhibited the conversion of single chain tissue plasminogen activator (sct-PA) to its two chain form (tct-PA) by plasmin. Tranexamic Acid 16-31 plasminogen Homo sapiens 80-87 2551068-4 1989 The addition of tranexamic acid to the mixture of sct-PA and K4 inhibited the rate of the conversion of sct-PA by plasmin. Tranexamic Acid 16-31 plasminogen Homo sapiens 114-121 2538425-1 1989 After incubation of confluent monolayer cultures of human HT-1080 fibrosarcoma cells with purified native human plasminogen in plasminogen-depleted serum-containing medium, bound plasmin activity could be specifically eluted from the cells with tranexamic acid, an analogue of lysine. Tranexamic Acid 245-260 plasminogen Homo sapiens 112-119 2523891-2 1989 We found that after incubation of monolayer cultures with purified native human plasminogen in serum-containing medium, bound plasmin activity could be eluted from the cells with tranexamic acid, an analogue of lysine. Tranexamic Acid 179-194 plasminogen Homo sapiens 80-87 2569479-9 1989 Blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with tranexamic acid (IC50 of 5 mM) inhibited neutrophil adherence. Tranexamic Acid 89-104 plasminogen Homo sapiens 33-40 2943320-7 1986 A rate constant, kcat/Km = 4.4 X 10(3) M-1 X s-1 is obtained for the reaction between plasmin and Glu-1-plasminogen in the presence of 1 mM trans-4-(aminomethyl)cyclohexane-1-carboxylic acid. Tranexamic Acid 140-190 plasminogen Homo sapiens 86-93 3394116-1 1988 Glu-plasminogen (Glu-plg) was degraded by elastase in the presence or absence of tranexamic acid. Tranexamic Acid 81-96 plasminogen Homo sapiens 21-24 3394116-2 1988 Glu-plg was degraded faster in the presence of tranexamic acid. Tranexamic Acid 47-62 plasminogen Homo sapiens 4-7 2441605-5 1987 Other ovaries were pretreated with trans-4-(aminomethyl)-cyclohexane-carboxylic acid, an inhibitor of the conversion of plasminogen to plasmin, and then perfused with human chorionic gonadotropin (50 IU). Tranexamic Acid 35-84 plasminogen Homo sapiens 120-127 2953634-4 1987 Treatment with AMCA significantly reduced both plasminogen activator (p less than 0.01) and plasmin (p less than 0.05) in the menstrual blood of patients with menorrhagia (Group 3). Tranexamic Acid 15-19 plasminogen Homo sapiens 47-54 2934862-2 1985 Increases in plasma activity by 125I-fibrin assay were similar (mean increase, 3- to 4-fold) to those observed by euglobulin lysis, and were inhibited (90-93% inhibition) by tranexamic acid at a concentration (10 mmol/l) which inhibits plasmin-mediated fibrinolysis. Tranexamic Acid 174-189 plasminogen Homo sapiens 236-243 2933845-5 1985 In the presence of 1 mM tranexamic acid, the conversion of both Glu-plg I and II to their Lys-forms by plasmin was accelerated and completed in 30 min incubation. Tranexamic Acid 24-39 plasminogen Homo sapiens 103-110 2933845-8 1985 Another observation was that tranexamic acid protected the degradation of plasminogen by plasmin, indicating the involvement of the lysine binding sites (LBS) of plasmin in the proteolytic attack against plg. Tranexamic Acid 29-44 plasminogen Homo sapiens 74-81 2933845-8 1985 Another observation was that tranexamic acid protected the degradation of plasminogen by plasmin, indicating the involvement of the lysine binding sites (LBS) of plasmin in the proteolytic attack against plg. Tranexamic Acid 29-44 plasminogen Homo sapiens 89-96 2934862-7 1985 Thus, the fibrinolytic response to exercise in the majority of normal individuals includes not only the well-known plasmin-mediated increase in plasma, which is inhibitable by tranexamic acid, but also a similar increment in cell-mediated activity, which is due to qualitative functional rather than quantitative changes in one or more as yet unidentified cell types, acting alone or in conjunction with plasma factors which are not inhibited by tranexamic acid. Tranexamic Acid 176-191 plasminogen Homo sapiens 115-122 2934862-7 1985 Thus, the fibrinolytic response to exercise in the majority of normal individuals includes not only the well-known plasmin-mediated increase in plasma, which is inhibitable by tranexamic acid, but also a similar increment in cell-mediated activity, which is due to qualitative functional rather than quantitative changes in one or more as yet unidentified cell types, acting alone or in conjunction with plasma factors which are not inhibited by tranexamic acid. Tranexamic Acid 446-461 plasminogen Homo sapiens 115-122 6449829-2 1980 Incubation of plasma from rats pretreated with tranexamic acid (40 mg/100 g) with acetone (23% V/V) yielded enzyme preparations in which all the plasminogen present was recovered as plasmin and a plasmin-like substance without affinity for lysine-Sepharose. Tranexamic Acid 47-62 plasminogen Homo sapiens 145-152 6459779-3 1981 This binding is decreased by alpha(2)-plasmin inhibitor and tranexamic acid, and is, in the latter case, related to saturation of a strong lysine-binding site. Tranexamic Acid 60-75 plasminogen Homo sapiens 38-45 6201189-2 1984 Clearance of the complexes from the blood is rapid and their detection thus implies active plasmin generation at the time of blood sampling or within the preceding 24 h. Abolition of the complexes using tranexamic acid therapy allowed surgery without bleeding in two previously grossly haemorrhagic patients in group (c). Tranexamic Acid 203-218 plasminogen Homo sapiens 91-98 6449829-2 1980 Incubation of plasma from rats pretreated with tranexamic acid (40 mg/100 g) with acetone (23% V/V) yielded enzyme preparations in which all the plasminogen present was recovered as plasmin and a plasmin-like substance without affinity for lysine-Sepharose. Tranexamic Acid 47-62 plasminogen Homo sapiens 182-189 125463-1 1975 Specific binding of tranexamic acid to plasmin. Tranexamic Acid 20-35 plasminogen Homo sapiens 39-46 6450467-10 1980 Plasmin stability is improved in the presence of AMCHA. Tranexamic Acid 49-54 plasminogen Homo sapiens 0-7 6157220-0 1980 Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid. Tranexamic Acid 105-120 plasminogen Homo sapiens 15-22 6447383-7 1980 In an even purified system, clot formation and the presence of tranexamic acid protected plasmin from its inactivation by alpha 2PI to some extent. Tranexamic Acid 63-78 plasminogen Homo sapiens 89-96 6447383-0 1980 Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot. Tranexamic Acid 28-43 plasminogen Homo sapiens 15-22 6447383-1 1980 Interaction of urokinase (UK) activated plasmin with tranexamic acid and alpha 2 plasmin inhibitor (alpha 2PI) was studied by using a chromogenic substrate (S-2251) and immunoelectrophoresis. Tranexamic Acid 53-68 plasminogen Homo sapiens 40-47 117680-3 1979 Evidence that tranexamic acid, a potent antiplasmin compound, provided an inhibitory effect on the cold activation of complement, suggested that the phenomenon could not be explained by a single mechanism, and plasmin might be involved in the phenomenon in a limited case. Tranexamic Acid 14-29 plasminogen Homo sapiens 44-51 150862-1 1978 The effects of L-lysine, 6-aminohexanoic acid, and trans-4-aminomethylcy-clohexane-1-carboxylic acid on the catalytic activity of plasmin (EC 3.4.21.7) have been investigated. Tranexamic Acid 51-100 plasminogen Homo sapiens 130-137 125463-6 1975 in the binding studies with the highly purified plasminogen and TLCK-plasmin preparations which were obtained by affinity chromatography on lysine-substituted Sepharose, the molar binding ratio was shown to be 1.5-1.6 moles tranexamic acid per one mole protein. Tranexamic Acid 224-239 plasminogen Homo sapiens 48-55 125463-4 1975 On the other hand, tranexamic acid bound to human plasmin with a dissociation constant of 3.5 X 10-5 M, which was very close to the inhibition constatn (3.6 X 10-5 M1 for this compound in inhibiting plasmin-induced fibrinolysis. Tranexamic Acid 19-34 plasminogen Homo sapiens 50-57 125463-4 1975 On the other hand, tranexamic acid bound to human plasmin with a dissociation constant of 3.5 X 10-5 M, which was very close to the inhibition constatn (3.6 X 10-5 M1 for this compound in inhibiting plasmin-induced fibrinolysis. Tranexamic Acid 19-34 plasminogen Homo sapiens 199-206 125463-5 1975 The binding site of tranexamic acid on plasmin was not the catalytic site of plasmin, because TLCK-blocked plasmin also showed a similar affinity to tranexamic acid (the dissociation constant, 2.9-4.8 x 10-5m). Tranexamic Acid 20-35 plasminogen Homo sapiens 39-46 125463-5 1975 The binding site of tranexamic acid on plasmin was not the catalytic site of plasmin, because TLCK-blocked plasmin also showed a similar affinity to tranexamic acid (the dissociation constant, 2.9-4.8 x 10-5m). Tranexamic Acid 149-164 plasminogen Homo sapiens 39-46 33518674-5 2021 Tranexamic acid (TXA), which is an anti-inflammatory medicine that inhibits plasmin, reduces the level of PGE2 secreted following UV exposure or after inflammatory stimulation. Tranexamic Acid 0-15 plasminogen Homo sapiens 76-83 33164754-1 2021 Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation. Tranexamic Acid 0-15 plasminogen Homo sapiens 80-87 33164754-1 2021 Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen to plasmin, a key step in kallikrein activation and bradykinin formation. Tranexamic Acid 17-20 plasminogen Homo sapiens 80-87 33443933-0 2021 Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. Tranexamic Acid 0-15 plasminogen Homo sapiens 72-79 33443933-1 2021 Tranexamic acid (TXA) is a lysine analogue that inhibits plasmin generation and has been used for decades as an antifibrinolytic agent to reduce bleeding. Tranexamic Acid 0-15 plasminogen Homo sapiens 57-64 33443933-1 2021 Tranexamic acid (TXA) is a lysine analogue that inhibits plasmin generation and has been used for decades as an antifibrinolytic agent to reduce bleeding. Tranexamic Acid 17-20 plasminogen Homo sapiens 57-64 33443933-2 2021 Recent reports have indicated that TXA can paradoxically promote plasmin generation. Tranexamic Acid 35-38 plasminogen Homo sapiens 65-72 33443933-9 2021 In contrast, PAP complex formation, representing plasmin generation, was unexpectedly enhanced in the plasma of patients administered TXA at the EOS time point. Tranexamic Acid 134-137 plasminogen Homo sapiens 49-56 33443933-11 2021 Our findings demonstrate that TXA can actually augment PAP complex formation, consistent with an increase in plasmin generation in vivo despite the fact that it blocks fibrinolysis within 30 min. Tranexamic Acid 30-33 plasminogen Homo sapiens 109-116 33518674-5 2021 Tranexamic acid (TXA), which is an anti-inflammatory medicine that inhibits plasmin, reduces the level of PGE2 secreted following UV exposure or after inflammatory stimulation. Tranexamic Acid 17-20 plasminogen Homo sapiens 76-83 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 75-82 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 122-129 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 122-129 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 171-186 plasminogen Homo sapiens 75-82 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 171-186 plasminogen Homo sapiens 122-129 34035635-4 2021 Tranexamic acid is known to competitively block the lysine-binding site of plasminogen and thus inhibit the activation of plasminogen to plasmin and at high-concentration tranexamic acid noncompetitively blocks plasmin, thus inhibiting the dissolution and degradation of fibrin clots by plasmin. Tranexamic Acid 171-186 plasminogen Homo sapiens 122-129 32701529-2 2020 Tranexamic acid (TXA) prevents ultraviolet radiation induced pigmentation in melasma through interfering with the plasminogen-plasmin pathway. Tranexamic Acid 0-15 plasminogen Homo sapiens 114-121 33001565-0 2021 Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. Tranexamic Acid 79-94 plasminogen Homo sapiens 17-24 33001565-2 2021 TXA inhibits plasmin(ogen) binding to fibrin and reduces fibrinolysis. Tranexamic Acid 0-3 plasminogen Homo sapiens 13-20 33001565-12 2021 For all doses of TXA administered intravenously, the PG assay detected delayed time-to-peak (<=3 hours) and reduced the velocity, peak, and endogenous plasmin potential (<=24 hours) in plasma samples obtained post-infusion. Tranexamic Acid 17-20 plasminogen Homo sapiens 151-158 32732500-2 2020 Tranexamic acid (TXA) has recently been used to treat bleeding in trauma by preventing plasmin generation to limit fibrinolysis. Tranexamic Acid 0-15 plasminogen Homo sapiens 87-94 32732500-2 2020 Tranexamic acid (TXA) has recently been used to treat bleeding in trauma by preventing plasmin generation to limit fibrinolysis. Tranexamic Acid 17-20 plasminogen Homo sapiens 87-94 33230046-0 2020 Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid? Tranexamic Acid 185-200 plasminogen Homo sapiens 0-7 33208180-2 2020 Tranexamic acid (TXA) reversibly blocks lysine binding sites on plasminogen molecules and inhibits plasmin formation. Tranexamic Acid 0-15 plasminogen Homo sapiens 64-71 33208180-2 2020 Tranexamic acid (TXA) reversibly blocks lysine binding sites on plasminogen molecules and inhibits plasmin formation. Tranexamic Acid 17-20 plasminogen Homo sapiens 64-71 32701529-2 2020 Tranexamic acid (TXA) prevents ultraviolet radiation induced pigmentation in melasma through interfering with the plasminogen-plasmin pathway. Tranexamic Acid 17-20 plasminogen Homo sapiens 114-121 32567734-2 2020 Tranexamic acid, a plasmin inhibitor, has demonstrated hypopigmenting properties. Tranexamic Acid 0-15 plasminogen Homo sapiens 19-26 31658420-5 2020 Furthermore, four types of promising active site inhibitors of plasmin have been developed: tranexamic acid conjugates targeting the S1 pocket and primed sites, substrate-analogue linear homopiperidylalanine-containing 4-amidinobenzylamide derivatives, macrocyclic inhibitors addressing nonprimed binding regions, and bicyclic 14-mer SFTI-1 analogues blocking both, primed and nonprimed binding sites of plasmin. Tranexamic Acid 92-107 plasminogen Homo sapiens 63-70 32064426-2 2020 Conversely, tranexamic acid (TXA) functions by inhibiting the conversion of plasminogen to plasmin, which inhibits fibrinolysis. Tranexamic Acid 12-27 plasminogen Homo sapiens 76-83 32819728-1 2020 INTRODUCTION: Tranexamic Acid (TXA), an antifibrinolytic that inhibits the fibrinolytic activity of plasmin is used to decrease perioperative blood loss and transfusion requirements in orthopedic surgery. Tranexamic Acid 14-29 plasminogen Homo sapiens 100-107 32819728-1 2020 INTRODUCTION: Tranexamic Acid (TXA), an antifibrinolytic that inhibits the fibrinolytic activity of plasmin is used to decrease perioperative blood loss and transfusion requirements in orthopedic surgery. Tranexamic Acid 31-34 plasminogen Homo sapiens 100-107 32064426-2 2020 Conversely, tranexamic acid (TXA) functions by inhibiting the conversion of plasminogen to plasmin, which inhibits fibrinolysis. Tranexamic Acid 29-32 plasminogen Homo sapiens 76-83 31126915-1 2019 Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation. Tranexamic Acid 0-15 plasminogen Homo sapiens 63-70 31489276-1 2019 Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by binding to its lysine receptor sites and preventing its conversion to plasmin. Tranexamic Acid 0-15 plasminogen Homo sapiens 66-73 31489276-1 2019 Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by binding to its lysine receptor sites and preventing its conversion to plasmin. Tranexamic Acid 17-20 plasminogen Homo sapiens 66-73 31126915-1 2019 Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation. Tranexamic Acid 17-20 plasminogen Homo sapiens 63-70 31126915-2 2019 Because plasmin is known to promote inflammatory and immunosuppressive responses, we explored the possibility that plasmin-mediated immunosuppression in patients undergoing cardiac surgery can be directly reversed by TXA and decrease postoperative infection rates. Tranexamic Acid 217-220 plasminogen Homo sapiens 115-122 31126915-9 2019 TXA was also shown to exert an immune-modulatory effect in healthy volunteers, further supporting the fibrin-independent effect of TXA on immune function and indicating that baseline plasmin levels contribute to the regulation of the immune system in the absence of any comorbidity or surgical trauma. Tranexamic Acid 0-3 plasminogen Homo sapiens 183-190 30575685-0 2019 Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner. Tranexamic Acid 0-15 plasminogen Homo sapiens 108-119 31141852-2 2019 Tranexamic acid (TXA), a potent plasmin inhibitor, is proposed to control pigmentation by inhibiting the release of inflammatory mediators involved in triggering melanogenesis. Tranexamic Acid 0-15 plasminogen Homo sapiens 32-39 31141852-2 2019 Tranexamic acid (TXA), a potent plasmin inhibitor, is proposed to control pigmentation by inhibiting the release of inflammatory mediators involved in triggering melanogenesis. Tranexamic Acid 17-20 plasminogen Homo sapiens 32-39 30575685-14 2019 CONCLUSIONS: Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator. Tranexamic Acid 13-28 plasminogen Homo sapiens 135-142 30575685-14 2019 CONCLUSIONS: Tranexamic acid administration can have proinflammatory or anti-inflammatory effects through regulating C5a generation by plasmin, depending on the predominating PLG activator. Tranexamic Acid 13-28 plasminogen Homo sapiens 175-178 30575685-15 2019 Tranexamic acid may cause significant inflammatory C5a elevations in injured tissues by augmenting uPA-mediated plasmin generation in a fibrin-independent manner. Tranexamic Acid 0-15 plasminogen Homo sapiens 112-119 30451372-3 2019 Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting. Tranexamic Acid 12-27 plasminogen Homo sapiens 37-44 30451372-10 2019 Results IC50 values for antifibrinolytic activity of TXA varied from < 10 to > 1000 mumol L-1 depending on the system, but good fibrin protection was observed in the presence of tPA, uPA and plasmin. Tranexamic Acid 53-56 plasminogen Homo sapiens 191-198 30451372-11 2019 However, in plasma or blood, active plasmin was generated by TXA + uPA (but not tPA) and coagulopathy developed leading to no or poor clot formation. Tranexamic Acid 61-64 plasminogen Homo sapiens 36-43 30451372-16 2019 Conclusions Tranexamic acid protects fibrin but stimulates uPA activity and slows inhibition of plasmin by alpha2 -antiplasmin. Tranexamic Acid 12-27 plasminogen Homo sapiens 96-103 30451372-18 2019 Additional direct inhibition of plasmin by aprotinin may prevent development of coagulopathy and extend the useful time window of TXA treatment. Tranexamic Acid 130-133 plasminogen Homo sapiens 32-39 30575685-2 2019 Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis. Tranexamic Acid 0-15 plasminogen Homo sapiens 66-73 30575685-2 2019 Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis. Tranexamic Acid 0-15 plasminogen Homo sapiens 107-114 30575685-2 2019 Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis. Tranexamic Acid 17-20 plasminogen Homo sapiens 66-73 30575685-2 2019 Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis. Tranexamic Acid 17-20 plasminogen Homo sapiens 107-114 30575685-4 2019 Because TXA does not block uPA-dependent plasmin generation from PLG and instead augments it, we hypothesized that administration of TXA could enhance or inhibit proinflammatory C5a formation in a PLG activator-dependent manner. Tranexamic Acid 133-136 plasminogen Homo sapiens 197-200 30575685-10 2019 RESULTS: Plasmin-mediated fibrinolysis by tPA in clotted PPP led to an approximately threefold increase in C5a production (p < 0.0001), which was significantly inhibited by TXA (p < 0.001). Tranexamic Acid 173-176 plasminogen Homo sapiens 9-16 29498767-7 2018 Moreover, the results confirm that activation of MMP-1 depends on increased plasmin activity in this model and lattice miniaturization was inhibited by the plasmin inhibitor tranexamic acid. Tranexamic Acid 174-189 plasminogen Homo sapiens 76-83 29926296-0 2018 The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis. Tranexamic Acid 53-68 plasminogen Homo sapiens 82-89 30253023-1 2018 Tranexamic acid (TXA), a plasmin inhibitor, is an antifibrinolytic drug widely used to prevent and treat hemorrhage. Tranexamic Acid 0-15 plasminogen Homo sapiens 25-32 30253023-1 2018 Tranexamic acid (TXA), a plasmin inhibitor, is an antifibrinolytic drug widely used to prevent and treat hemorrhage. Tranexamic Acid 17-20 plasminogen Homo sapiens 25-32 29498767-7 2018 Moreover, the results confirm that activation of MMP-1 depends on increased plasmin activity in this model and lattice miniaturization was inhibited by the plasmin inhibitor tranexamic acid. Tranexamic Acid 174-189 plasminogen Homo sapiens 156-163 26177992-3 2015 Tranexamic acid (TA), a plasmin inhibitor, is reported to improve melasma when injected locally or used as oral and topical forms. Tranexamic Acid 0-15 plasminogen Homo sapiens 24-31 26538719-2 2015 Tranexamic acid, a plasmin inhibitor, has demonstrated depigmenting properties and combining this oral drug with other modalities of treatment has shown promising results. Tranexamic Acid 0-15 plasminogen Homo sapiens 19-26 28678111-4 2018 TXA competitively inhibits plasmin and batroxobin converts fibrinogen to fibrin and theoretically their combination is synergistic. Tranexamic Acid 0-3 plasminogen Homo sapiens 27-34 29354728-1 2017 Background: Tranexamic acid is a synthetic lysine-analogue antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, it is a well-documented blood sparing agent. Tranexamic Acid 12-27 plasminogen Homo sapiens 122-129 27173008-2 2017 Tranexamic acid has been found to lighten melasma by interfering with the interaction of melanocytes and keratinocytes by inhibiting the plasminogen/plasmin system. Tranexamic Acid 0-15 plasminogen Homo sapiens 137-144 28601310-8 2017 Tranexamic acid (TXA) was added to inhibit plasmin-dependent fibrinolysis. Tranexamic Acid 0-15 plasminogen Homo sapiens 43-50 28601310-8 2017 Tranexamic acid (TXA) was added to inhibit plasmin-dependent fibrinolysis. Tranexamic Acid 17-20 plasminogen Homo sapiens 43-50 29296720-0 2017 X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors. Tranexamic Acid 40-55 plasminogen Homo sapiens 27-34 29296720-4 2017 Currently, tranexamic acid (TXA), a molecule that prevents plasminogen activation through blocking recruitment to target substrates, is the most widely used inhibitor for the plasminogen/plasmin system in therapeutics. Tranexamic Acid 11-26 plasminogen Homo sapiens 59-66 29296720-4 2017 Currently, tranexamic acid (TXA), a molecule that prevents plasminogen activation through blocking recruitment to target substrates, is the most widely used inhibitor for the plasminogen/plasmin system in therapeutics. Tranexamic Acid 28-31 plasminogen Homo sapiens 59-66 29296720-9 2017 Here, the TXA moiety of the YO compounds inserts into the primary (S1) specificity pocket, suggesting that TXA itself may function as a weak plasmin inhibitor, a hypothesis supported by subsequent biochemical and biophysical analyses. Tranexamic Acid 10-13 plasminogen Homo sapiens 141-148 29296720-9 2017 Here, the TXA moiety of the YO compounds inserts into the primary (S1) specificity pocket, suggesting that TXA itself may function as a weak plasmin inhibitor, a hypothesis supported by subsequent biochemical and biophysical analyses. Tranexamic Acid 107-110 plasminogen Homo sapiens 141-148 26177992-3 2015 Tranexamic acid (TA), a plasmin inhibitor, is reported to improve melasma when injected locally or used as oral and topical forms. Tranexamic Acid 17-19 plasminogen Homo sapiens 24-31 25747626-1 2015 INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic Acid 14-29 plasminogen Homo sapiens 105-112 25747626-1 2015 INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic Acid 31-34 plasminogen Homo sapiens 105-112 23967870-1 2014 BACKGROUND: Tranexamic acid (TA) is a traditional plasmin inhibitor, and its role in the renovation of damaged skin has become the topic of a lot of research. Tranexamic Acid 12-27 plasminogen Homo sapiens 50-57 24756178-1 2015 INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. Tranexamic Acid 14-29 plasminogen Homo sapiens 111-118 24756178-1 2015 INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin. Tranexamic Acid 31-34 plasminogen Homo sapiens 111-118 24659483-4 2014 Tranexamic acid and epsilon-aminocaproic acid, two small molecule plasmin inhibitors, are currently used in the clinic. Tranexamic Acid 0-15 plasminogen Homo sapiens 66-73 23967870-1 2014 BACKGROUND: Tranexamic acid (TA) is a traditional plasmin inhibitor, and its role in the renovation of damaged skin has become the topic of a lot of research. Tranexamic Acid 29-31 plasminogen Homo sapiens 50-57 22329442-2 2013 Tranexamic acid (TXA), a plasmin inhibitor, is reported to improve melasma when injected locally. Tranexamic Acid 0-15 plasminogen Homo sapiens 25-32 23661406-6 2013 In the UK, tranexamic acid, a tissue plasminogen and plasmin inhibitor, is most commonly used, with evidence for benefit in cardiac, orthopaedic, urological, gynaecological, and obstetric surgery. Tranexamic Acid 11-26 plasminogen Homo sapiens 37-44 22329442-2 2013 Tranexamic acid (TXA), a plasmin inhibitor, is reported to improve melasma when injected locally. Tranexamic Acid 17-20 plasminogen Homo sapiens 25-32 20185649-0 2010 Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Tranexamic Acid 71-86 plasminogen Homo sapiens 51-58 23261456-6 2013 Furthermore, injection of tranexamic acid, a plasmin inhibitor, more markedly reduced MMP-9 and MMP-2 activity and angiogenesis in tumors originating from progalanin siRNA-treated SBC-3A cells and in tumor tissue originating from progalanin siRNA-treated SBC-3A cells in the presence of progalanin. Tranexamic Acid 26-41 plasminogen Homo sapiens 45-52 21707521-10 2011 In addition, tranexamic acid, a plasmin inhibitor, inhibited progalanin conversion to galanin(1-20). Tranexamic Acid 13-28 plasminogen Homo sapiens 32-39 20185649-2 2010 Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients. Tranexamic Acid 138-153 plasminogen Homo sapiens 82-89 20185649-2 2010 Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients. Tranexamic Acid 155-158 plasminogen Homo sapiens 82-89 19207486-9 2009 RESULTS: Tranexamic acid alone and in combination with CTT1 can inhibit tongue SCC invasion in vitro, at least partially explained by its property of reducing the plasmin-mediated activation of proMMP-9. Tranexamic Acid 9-24 plasminogen Homo sapiens 163-170 19104179-9 2009 RESULTS: With its high affinity for plasmin (Ki, 2 nM), CU-2010 inhibited fibrinolysis comparable to aprotinin (Ki, 4 nM) and was ten times more potent than tranexamic acid. Tranexamic Acid 157-172 plasminogen Homo sapiens 36-43 18460030-13 2008 The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure. Tranexamic Acid 62-77 plasminogen Homo sapiens 85-92 18460030-13 2008 The addition of aprotinin, a serine proteinase inhibitor, and tranexamic acid, a uPA-plasmin inhibitor, inhibited the plasmin-induced impairment of BM assembly and facilitated BM reorganization, thereby improving the epidermal structure. Tranexamic Acid 62-77 plasminogen Homo sapiens 118-125